Taxanes in the treatment of early breast cancer

Cancer Treatment Reviews

Volumn 31, Issue 8, 2005, Pages 618-627

  Ring, Alistair E ^a   Ellis, Paul A ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Breast cancer; Docetaxel; Neoadjuvant; Paclitaxel; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

AMENORRHEA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; HUMAN; LETHARGY; LYMPH NODE METASTASIS; METASTASIS; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PREDICTION; QUALITY OF LIFE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; TAXOIDS;

EID: 27944508718     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.09.005     Document Type: Article

References (39)

1. R.E. Smith A.M. Brown E.P. Mamounas et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26 J Clin Oncol 17 11 1999 3403-3411
2. R. Paridaens L. Biganzoli P. Bruning et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over J Clin Oncol 18 4 2000 724-733
3. S. Chan K. Friedrichs D. Noel et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group J Clin Oncol 17 8 1999 2341-2354
4. J.F. Bishop J. Dewar G.C. Toner et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer J Clin Oncol 17 8 1999 2355-2364
5. D.P. Figgitt L.R. Wiseman Docetaxel: An update of its use in advanced breast cancer Drugs 59 3 2000 621-651
6. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352(9132):930-942.
7. Henderson IC, Berry D, Demetri G, et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. In: Proceedings of the American Society of Clinical Oncology 1998, abstract 390.
8. M.J. Piccart J. Klastersky F. Meunier H. Lagast Y. VanLaethem D. Weerts Taxanes in the adjuvant treatment of breast cancer: Why not yet? J Natl Cancer Inst Monogr 0 30 2001 88-95
9. I.C. Henderson D.A. Berry G.D. Demetri et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 6 2003 976-983
10. Mamounas EP. Evaluating the use of paclitaxel following doxorubicin/ cyclophosphamide in patients with breast cancer and positive axillary nodes. In: Adjuvant therapy for breast cancer. NIH Consensus Statement, November 1-3, 2000.
11. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotehrapy for node-positive breast cancer: Results from NSABP B28. In: Proceedings of the American Society of Clinical Oncology 2003, abstract 12.
12. Albain KS, Green SJ, Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). In: Proceedings of the American Society of Clinical Oncology 2002, abstract 143.
13. Thomas E, Buzdar A, Theriault R, et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: Preliminary results of prospective randomized clinical trial. In: Proceedings of the American Society of Clinical Oncology 2000, abstract 285.
14. A.U. Buzdar S.E. Singletary V. Valero et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial Clin Cancer Res 8 5 2002 1073-1079
15. Roché H, Fumoleau P, Spielmann M, et al. Five year analysis of the PACS01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. In: Proceedings of the San Antonio Breast Cancer Symposium, 2004, abstract 27.
16. M. Martin T. Pienkowski J. Mackey et al. Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2005 2302-2313
17. Gianni L, Baselga J, Eiermann W, et al. European Cooperative Trial in operable breast cancer (ECTO): Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. In: Proceedings of the American Society of Clinical Oncology 2005, abstract 513.
18. M.L. Citron D.A. Berry C. Cirrincione et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 8 2003 1431-1439
19. Fumoleau P, Bremond A, Kerbrat P, et al. Better outcome of premenopausal node-positive breast cancer patients treated with 6 cycles vs. 3 cycles of adjuvant chemotherapy: Eight year follow-up results of FASG 01. In: Proceedings of the American Society of Clinical Oncology 1999, abstract 252.
20. Martin M, Lluch A, Segui MA, et al. Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide for node-negative breast cancer: An interim safety analysis of the GEICAM 9805 study. In: Proceedings of the American Society of Oncology 2004, abstract 620.
21. L.J. van't Veer H. Dai van de Vijver et al. Gene expression profiling predicts clinical outcome of breast cancer Nature 415 6871 2002 530-536
22. M.J. van de Vijver Y.D. He L.J. van't Veer et al. A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 25 2002 1999-2009
23. J.C. Chang E.C. Wooten A. Tsimelzon et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 9381 2003 362-369
24. S.M. Scholl A. Fourquet B. Asselain et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6 Eur J Cancer A 30 5 1994 645-652
25. T.J. Powles T.F. Hickish A. Makris et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer J Clin Oncol 13 3 1995 547-552
26. B. Fisher J. Bryant N. Wolmark et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 8 1998 2672-2685
27. H.M. Kuerer L.A. Newman T.L. Smith et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 2 1999 460-469
28. P. Ellis I. Smith S. Ashley et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer J Clin Oncol 16 1 1998 107-114
29. A.U. Buzdar S.E. Singletary R.L. Theriault et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer J Clin Oncol 17 11 1999 3412-3417
30. H.D. Bear S. Anderson A. Brown et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 22 2003 4165-4174
31. Bear HD, Anderson S, Smith RE, et al. A randomised trial comparing preoperative doxorubicin/cyclophosphamide to preoperative AC followed by preoperative docetaxel and to preoperative AC followed by postoperative docetaxel in patients with operable carcinoma of the breast: Results of the NSABP B27 trial. In: Proceedings of the San Antonio Breast Cancer Symposium, 2004, abstract 26.
32. I.C. Smith S.D. Heys A.W. Hutcheon et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel J Clin Oncol 20 6 2002 1456-1466
33. Hutcheon AW, Heys SD, Sarkar TK, et al. Docetaxel primary chemotherapy in breast cancer: A five year update of the Aberdeen trial. In: Proceedings of the San Antonio Breast Cancer Symposium 2003, abstract 11.
34. Gianni L, Baselga J, Eiermann W, et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): Effects of primary systemic therapy on loco-regional disease. In: Proceedings of the American Society of Clinical Oncology 2002, abstract 132.
35. Untch M, Konecny G, Ditsch N, et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. In: Proceedings of the American Society of Clinical Oncology 2002, abstract 133.
36. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel followed by FAC in the neo-adjuvant setting provides improved pathological complete remission rates compared to standard paclitaxel followed by FAC therapy: preliminary results of an ongoing prospective randomized trial. In: Proceedings of the American Society of Clinical Oncology 2001, abstract 129.
37. Hurley J, Doliny P, Silva O, et al. Neoadjuvant herceptin/taxotee/ cisplatin in the treatment of locally advanced and inflammatory breast cancer. In: Proceedings of the American Society of Clinical Oncology 2002, abstract 196.
38. H.J. Burstein L.N. Harris R. Gelman et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study J Clin Oncol 21 1 2003 46-53
39. Goldstein L, O'Neill A, Sparano E, et al. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. In: Proceedings of the American Society of Clinical Oncology 2005, abstract 512.